Financial Projections - Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for Q4 2025 and approximately $30.9 million for the full year 2025[1][4]. - As of December 31, 2025, Verastem reported cash, cash equivalents, and investments of $205 million, which increases to $234 million when including net proceeds from exercised cash warrants[1][4]. - The company anticipates that the LGSOC commercial launch and development program will be self-sustaining by the second half of 2026[1][4]. Clinical Trials and Development - The ongoing RAMP 301 Phase 3 trial for AVMAPKI FAKZYNJA CO-PACK is fully enrolled and aims to confirm the initial indication for KRAS-mutated recurrent LGSOC[1][5]. - In the RAMP 201J Phase 2 trial in Japan, a confirmed overall response rate (ORR) of 38% was achieved among 16 efficacy evaluable patients, with a 57% ORR in KRAS-mutated patients[1][5]. - Verastem plans to report a topline readout of the primary endpoint in the RAMP 301 trial in mid-2027[1][8]. - The company is advancing VS-7375, a selective oral KRAS G12D inhibitor, in an international Phase 1/2 trial for advanced KRAS G12D solid tumors[1][8]. - Verastem expects to provide an update on the safety and efficacy of the RAMP 205 expansion cohort in Q2 2026[1][9]. Regulatory Approvals and Collaborations - The FDA approved AVMAPKI™ FAKZYNJA™ CO-PACK for KRAS-mutated recurrent LGSOC on May 8, 2025, with continued approval contingent on confirmatory trial results[1][13]. - The collaboration with GenFleet Therapeutics aims to advance three oncology discovery programs related to RAS/MAPK pathway-driven cancers, with VS-7375 being the lead program[1][19]. - Verastem Oncology is focused on developing and commercializing new medicines for patients with RAS/MAPK pathway-driven cancers, with a pipeline that includes novel small molecule drugs targeting critical signaling pathways[21]. Product Information and Safety - The company markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S., which is designed to inhibit cancer cell survival and tumor growth[21]. - The company advises against the concomitant use of AVMAPKI FAKZYNJA CO-PACK with strong and moderate CYP3A4 inhibitors and inducers, as well as warfarin and certain gastric acid reducing agents[20]. - The use of AVMAPKI FAKZYNJA CO-PACK may impair fertility in both males and females[20]. Risks and Forward-Looking Statements - Forward-looking statements indicate potential risks and uncertainties related to the commercialization of product candidates and the conduct of clinical trials, which may affect actual results[22]. - There are risks associated with the FDA's review process, including potential delays and regulatory uncertainties that could impact product approval and commercialization[22]. - Investors are cautioned not to place considerable reliance on forward-looking statements due to inherent risks in research and development[22]. - The company’s Annual Report on Form 10-K for the year ended December 31, 2024, details additional risks and uncertainties[22]. Contact Information - For inquiries, the Vice President of Corporate Communications can be contacted via provided email addresses[23].

Exhibit 99.1 Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025 | | | | | | Quarter Ended | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | December | | September | | December | | | | | Dollars in millions, except per share data | 31, | | 30, | | 31, | | Change | | | | 2025 | | 2025 | | 2024 (1) | | Prior Qtr | Prior Yr. | | Revenue from Continuing Operations | $ | 149 | $ | 159 | $ | 147 | (7)% | 1% | | Organic growth | | | | | | | | (1)% | | Sample Management S ...

• Reported net sales of $7.1 billion, up 8% versus the prior year, exceeding our guidance. • Raising full-year net sales, adjusted operating margin and adjusted EPS guidance. • Delivered a record GAAP operating margin of 5.5%, and a record adjusted operating margin of 6.5%, our fifth consecutive quarter with an adjusted operating margin of 6% or greater. • Reported GAAP EPS of $0.64, and a record adjusted EPS of $0.87. P R E S S R E L E A S E EXHIBIT 99.1 FLEX REPORTS THIRD QUARTER FISCAL 2026 RESULTS Austi ...

Financial Performance - Revenues for the three months ended December 28, 2025, increased to CAD 760,653 thousand, up 16.7% from CAD 651,993 thousand in the same period last year[3] - Net income for the three months ended December 28, 2025, was CAD 30,033 thousand, compared to CAD 6,505 thousand for the same period in 2024, representing a significant increase of 361.5%[3] - Earnings per share attributable to shareholders for the three months ended December 28, 2025, were CAD 0.31, compared to CAD 0.07 in the prior year, reflecting a growth of 342.9%[3] - For the nine months ended December 28, 2025, the net income was CAD 87,937,000, compared to CAD 40,913,000 for the same period in 2024, representing a 114% increase[8] - Income before income taxes for the three months ended December 28, 2025, was $33,643 thousand, compared to $10,642 thousand for the same period in 2024, representing a 216% increase[61] Assets and Liabilities - Total assets decreased to CAD 4,482,793 thousand as of December 28, 2025, down from CAD 4,621,872 thousand as of March 31, 2025[2] - Total liabilities decreased to CAD 2,701,257 thousand as of December 28, 2025, compared to CAD 2,912,515 thousand as of March 31, 2025, indicating a reduction of 7.2%[2] - The company reported a total equity of CAD 1,781,536,000 as of December 28, 2025, up from CAD 1,756,040,000 as of December 29, 2024, reflecting an increase of 1.5%[6] - The total long-term debt as of December 28, 2025, was $1,365,711, a decrease from $1,543,678 on March 31, 2025[57] - The balance of warranty provisions at December 28, 2025, was $10,651, an increase from $10,362 at March 31, 2025[45] Cash Flow and Operating Costs - Cash and cash equivalents increased to CAD 263,088 thousand as of December 28, 2025, up from CAD 225,947 thousand as of March 31, 2025, showing a growth of 16.5%[2] - Operating costs for the three months ended December 28, 2025, were CAD 535,780 thousand, an increase from CAD 454,061 thousand in the same period last year, representing an increase of 17.9%[3] - Cash flows provided by operating activities for the nine months ended December 28, 2025, were CAD 298,881,000, a significant recovery from a cash outflow of CAD 13,555,000 in the same period of 2024[8] Comprehensive Income - Comprehensive income for the three months ended December 28, 2025, was CAD 7,820 thousand, down from CAD 65,008 thousand in the prior year, reflecting a decrease of 88.0%[4] - Total comprehensive income for the nine months ended December 28, 2025, was CAD 82,027,000, compared to CAD 122,620,000 for the same period in 2024, indicating a decrease of 33%[8] Acquisitions and Investments - The company engaged in business acquisitions, net of cash acquired, amounting to CAD 2,280,000 during the three months ended December 28, 2025[8] - The Company acquired 100% of Paxiom Group for a total purchase price of $146,438, with cash consideration of $136,515 after accounting for cash acquired[20][21]. - The Company also acquired Heidolph Instruments for $45,064, with cash consideration of $42,874 after accounting for cash acquired[25][27]. Inventory and Write-downs - As of December 28, 2025, inventories totaled $308,136, a decrease from $320,172 as of March 31, 2025[30]. - The amount charged to net income for inventory write-downs was $5,908 for the nine months ended December 28, 2025, compared to $3,073 for the same period in 2024[31]. Shareholder Information - The Company announced a normal course issuer bid allowing the repurchase of up to 8,225,621 common shares by December 21, 2026[58] - The Company’s common shares outstanding increased to 96,948,447 as of December 28, 2025, from 96,885,705 at March 31, 2025[60] Taxation - The effective income tax rate for the nine months ended December 28, 2025, was 25%, down from 29% in the same period in 2024, resulting in an income tax expense of $28,678 thousand compared to $16,438 thousand[61] - The company recognized income tax expense related to the Global Minimum Tax Act of $605 thousand and $1,777 thousand for the three and nine months ended December 28, 2025, respectively[63] Risk Management - For the three and nine months ended December 28, 2025, the Company recorded risk management losses of $2,586 and $1,108, respectively, compared to losses of $13,310 and $17,501 for the same periods in 2024[44] - The Company is monitoring the global tariff environment but has not seen a material impact on its financial position or operations[19]. IFRS Standards - The Company expects the adoption of new IFRS standards, including IFRS 18, to improve financial statement transparency starting January 1, 2027[13].

Exhibit 99 Silicon Labs Reports Fourth Quarter and Full Year 2025 Results AUSTIN, Texas – February 4, 2026 – Silicon Labs (NASDAQ: SLAB), a leader in secure, intelligent wireless technology for a more connected world, reported financial results for the fourth quarter and full year 2025, which ended January 3, 2026. "The Silicon Labs team completed fiscal 2025 with continued strong execution, delivering an impressive year-over-year revenue growth of 34%," said Matt Johnson, President and Chief Executive Offi ...

SOUTHFIELD, Mich., February 4, 2026 -- Lear Corporation (NYSE: LEA), a global automotive technology leader in Seating and E-Systems, today reported results for the fourth quarter and full year 2025 and provided its financial outlook for the full year 2026. Fourth Quarter 2025 Highlights FOR IMMEDIATE RELEASE Lear Contacts: Marianne Vidershain (248) 447-5541 Tim Brumbaugh (248) 447-1329 Lear Reports Fourth Quarter and Full Year 2025 Results (more) • Delivered revenue of $6.0 billion in the fourth quarter, an ...

Exhibit 99.1 Media contact Investor contact Timothy Barello, 212.299.2256 Adam Minick, 312.340.8365 Laurie Bischel, 312.648.8698 investors@cmegroup.com news@cmegroup.com CME-G cmegroup.mediaroom.com FOR IMMEDIATE RELEASE CME Group Inc. Reports Fourth Consecutive Year of Record Annual Revenue, Adjusted Operating Income, Adjusted Net Income and Adjusted Earnings Per Share for 2025 CHICAGO, February 4, 2026 - CME Group Inc. (NASDAQ: CME) today reported financial results for the fourth quarter and full year of ...

EXHIBIT 99.1 CDW Reports Fourth Quarter and Full Year 2025 Earnings | Three Months Ended December 31, | | | | | | | | | | | | | | | | | Year Ended December 31, | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | (Dollars in millions, except per | | | | | | | | | | | | | | | | | | | Percent | | | Percent | | | | | | | | share amounts) | | | | | | | 2025 | | | 2 ...

NEWS RELEASE T. ROWE PRICE GROUP REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS n/m - the percentage change is not meaningful. Capital allocation-based income represents the change in accrued carried interest. See the reconciliation to the comparable U.S. GAAP measures at the end of this earnings release. Beginning July 1, 2025, managed account - model delivery assets are included in assets under management. (1) (2) (3) (4) 1 ▪ Assets under management (AUM) of $1.8 trillion at December 31, 2025 ▪ Net cli ...

February 4, 2026 For release: Immediately Refer to: Ashley Hennessey; gentry_ashley_jo@lilly.com; (317) 416-4363 (Media) Mike Czapar; czapar_michael_c@lilly.com; (317) 617-0983 (Investors) Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance INDIANAPOLIS, February 4, 2026 - Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth-quarter of 2025 and provided 2026 financial guidance. "2025 was an important year for Lilly," said David A. Ricks, Lilly's c ...